Showing results (181-190 of 319) with videos related to

Sort By:
Pageof 32
Neurourology and Urodynamics|January 23, 2018
Signs and symptoms that distinguish detrusor underactivity from mixed detrusor underactivity and bladder outlet obstruction in male patientsAndrew Gammie, Mathilde Kaper, Achim Steup, et al.
Neurourology and Urodynamics|April 5, 2011
How does neuromodulation workBastian Amend, Klaus E Matzel, Paul Abrams, et al.
BJU International|April 21, 2005
A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladderChristopher Chapple, William Steers, Peggy Norton, et al.
Neurourology and Urodynamics|April 11, 2018
What are the additional signs and symptoms in patients with detrusor underactivity and coexisting detrusor overactivity?Andrew Gammie, Mathilde Kaper, Achim Steup, et al.
Neurourology and Urodynamics|December 11, 2019
Bladder-bowel interactions: Do we understand pelvic organ cross-sensitization? International Consultation on Incontinence Research Society (ICI-RS) 2018Jalesh N Panicker, Tom Marcelissen, Alexander von Gontard, et al.
Neurourology and Urodynamics|February 14, 2016
Detrusor underactivity and the underactive bladder: Symptoms, function, cause-what do we mean? ICI-RS think tank 2014Phillip P Smith, Lori A Birder, Paul Abrams, et al.
BJU International|May 26, 2010
Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentrationChristopher R Chapple, Sender Herschorn, Paul Abrams, et al.
Journal of Health Services Research & Policy|November 5, 2003
Including a 'no active intervention' arm in surgical trials is possible: evidence from the CLasP randomised trialSara Brookes, Tim Peters, Rona Campbell, et al.
BJU International|March 8, 2008
Clinical relevance of health-related quality of life outcomes with darifenacinPaul Abrams, Con Kelleher, Jasper Huels, et al.
BJU International|April 29, 2006
Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinenceClaus G Roehrborn, Paul Abrams, Eric S Rovner, et al.
Pageof 32